• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CEUS LI-RADS 用于诊断无 LI-RADS 定义的肝癌危险因素的个体中的肝细胞癌。

CEUS LI-RADS for diagnosis of hepatocellular carcinoma in individuals without LI-RADS-defined hepatocellular carcinoma risk factors.

机构信息

Department of Medical Ultrasound, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Postal address 430030, Qiaokou District, Wuhan, Hubei Province, China.

出版信息

Cancer Imaging. 2023 Mar 6;23(1):24. doi: 10.1186/s40644-023-00541-2.

DOI:10.1186/s40644-023-00541-2
PMID:36879352
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9987139/
Abstract

PURPOSE

This study evaluated the performance of the contrast-enhanced ultrasound (CEUS) Liver Imaging Reporting and Data System (LI-RADS) in patients without LI-RADS-defined hepatocellular carcinoma (HCC) risk factors (RF-).

METHODS

Patients with LI-RADS-defined HCC risk factors (RF+) and RF- were enrolled in a retrospective study. Additionally, a prospective evaluation in the same centre was performed as a validation set. The diagnostic performances of the CEUS LI-RADS criteria in RF+ and RF- patients were compared.

RESULTS

Overall, we included 873 patients in the analyses. In the retrospective study, the LI-RADS category (LR)-5 specificities for diagnosing HCC did not differ between the RF+ and RF- groups (77.5% [158/204] vs 91.6% [196/214], P = 0.369, respectively). However, the positive predictive value (PPV) of CEUS LR-5 was 95.9% (162/169) and 89.8% (158/176) in the RF+ and RF- groups, respectively (P = 0.029). In the prospective study, the PPV of LR-5 for HCC lesions was significantly higher in the RF+ group than in the RF- group (P = 0.030). The sensitivity and specificity did not differ between the RF+ and RF- groups (P = 0.845 and P = 0.577, respectively).

CONCLUSIONS

The CEUS LR-5 criteria shows clinical value for diagnosis of HCC in patients with and without risks.

摘要

目的

本研究评估了增强超声(CEUS)肝脏成像报告和数据系统(LI-RADS)在无 LI-RADS 定义的肝细胞癌(HCC)风险因素(RF-)患者中的性能。

方法

LI-RADS 定义的 HCC 风险因素(RF+)和 RF-患者纳入回顾性研究。此外,在同一中心进行了前瞻性评估作为验证集。比较了 RF+和 RF-患者中 CEUS LI-RADS 标准的诊断性能。

结果

总体而言,我们对 873 名患者进行了分析。在回顾性研究中,RF+和 RF-组中诊断 HCC 的 CEUS LI-RADS 类别(LR)5 的特异性无差异(77.5%[158/204]与 91.6%[196/214],P=0.369)。然而,CEUS LR-5 的阳性预测值(PPV)在 RF+和 RF-组中分别为 95.9%(162/169)和 89.8%(158/176)(P=0.029)。在前瞻性研究中,LR-5 对 HCC 病变的 PPV 在 RF+组中显著高于 RF-组(P=0.030)。RF+和 RF-组之间的敏感性和特异性没有差异(P=0.845 和 P=0.577)。

结论

CEUS LR-5 标准对有和无风险的患者 HCC 的诊断具有临床价值。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/254c/9987139/5bb53b8051fd/40644_2023_541_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/254c/9987139/ee2917e1d11b/40644_2023_541_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/254c/9987139/12baa102d59d/40644_2023_541_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/254c/9987139/3faba7e357d8/40644_2023_541_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/254c/9987139/318f7366a93b/40644_2023_541_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/254c/9987139/5bb53b8051fd/40644_2023_541_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/254c/9987139/ee2917e1d11b/40644_2023_541_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/254c/9987139/12baa102d59d/40644_2023_541_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/254c/9987139/3faba7e357d8/40644_2023_541_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/254c/9987139/318f7366a93b/40644_2023_541_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/254c/9987139/5bb53b8051fd/40644_2023_541_Fig5_HTML.jpg

相似文献

1
CEUS LI-RADS for diagnosis of hepatocellular carcinoma in individuals without LI-RADS-defined hepatocellular carcinoma risk factors.CEUS LI-RADS 用于诊断无 LI-RADS 定义的肝癌危险因素的个体中的肝细胞癌。
Cancer Imaging. 2023 Mar 6;23(1):24. doi: 10.1186/s40644-023-00541-2.
2
Diagnostic accuracy of contrast-enhanced ultrasound for the differential diagnosis of hepatocellular carcinoma: ESCULAP versus CEUS-LI-RADS.超声造影对肝细胞癌鉴别诊断的诊断准确性:爱克发与CEUS-LI-RADS对比
Eur J Gastroenterol Hepatol. 2017 Sep;29(9):1036-1044. doi: 10.1097/MEG.0000000000000916.
3
MR versus CEUS LI-RADS for Distinguishing Hepatocellular Carcinoma from other Hepatic Malignancies in High-Risk Patients.磁共振成像与超声造影 LI-RADS 对高危患者肝细胞癌与其他肝脏恶性肿瘤的鉴别诊断
Ultrasound Med Biol. 2021 May;47(5):1244-1252. doi: 10.1016/j.ultrasmedbio.2021.01.020. Epub 2021 Feb 18.
4
Diagnostic Accuracy of CEUS LI-RADS for the Characterization of Liver Nodules 20 mm or Smaller in Patients at Risk for Hepatocellular Carcinoma.CEUS LI-RADS 在肝癌风险患者中对 20mm 或更小的肝脏结节的特征诊断准确性。
Radiology. 2020 Feb;294(2):329-339. doi: 10.1148/radiol.2019191086. Epub 2019 Dec 3.
5
The Value of CEUS LI-RADS combined with AFP in early diagnosis of hepatocellular carcinoma in low- and high-risk patients.CEUS LI-RADS 联合 AFP 对低危和高危人群肝细胞癌的早期诊断价值。
J Cancer Res Ther. 2024 Aug 1;20(4):1274-1283. doi: 10.4103/jcrt.jcrt_125_24. Epub 2024 Aug 29.
6
Contrast-enhanced ultrasound LI-RADS 2017: comparison with CT/MRI LI-RADS.对比增强超声 LI-RADS 2017:与 CT/MRI LI-RADS 的比较。
Eur Radiol. 2021 Feb;31(2):847-854. doi: 10.1007/s00330-020-07159-z. Epub 2020 Aug 15.
7
Differences between CEUS LI-RADS and CECT LI-RADS in the diagnosis of focal liver lesions in patients at risk for HCC.CEUS LI-RADS 与 CECT LI-RADS 在 HCC 高危患者局灶性肝脏病变诊断中的差异。
BMC Med Imaging. 2023 Sep 11;23(1):122. doi: 10.1186/s12880-023-01088-1.
8
Contrast-enhanced ultrasound Liver Imaging Reporting and Data System: Lights and shadows in hepatocellular carcinoma and cholangiocellular carcinoma diagnosis.超声造影肝脏影像报告与数据系统:在肝细胞癌和胆管细胞癌诊断中的优缺点。
World J Gastroenterol. 2022 Jul 21;28(27):3488-3502. doi: 10.3748/wjg.v28.i27.3488.
9
Contrast-Enhanced Ultrasound Using Perfluorobutane: Impact of Proposed Modified LI-RADS Criteria on Hepatocellular Carcinoma Detection.使用全氟丁烷的超声造影:拟议改良 LI-RADS 标准对肝细胞癌检测的影响。
AJR Am J Roentgenol. 2022 Sep;219(3):434-443. doi: 10.2214/AJR.22.27521. Epub 2022 Apr 20.
10
Diagnostic efficacy of contrast-enhanced ultrasound versus MRI Liver Imaging Reporting and Data System (LI-RADS) for categorising hepatic observations in patients at risk of hepatocellular carcinoma.超声造影与 MRI 肝脏影像报告与数据系统(LI-RADS)对肝癌高危患者肝脏观察病灶分类的诊断效能。
Clin Radiol. 2021 Feb;76(2):161.e1-161.e10. doi: 10.1016/j.crad.2020.10.009. Epub 2020 Nov 14.

引用本文的文献

1
Using four-point subcutaneous injection of lymphatic contrast-enhanced ultrasound to diagnose lymphedema of lower extremity.采用四点皮下注射淋巴造影增强超声诊断下肢淋巴水肿。
Quant Imaging Med Surg. 2024 Jul 1;14(7):4965-4971. doi: 10.21037/qims-24-300. Epub 2024 Jun 18.
2
A Modified Targetoid Feature Emphasizing Thin-Rim APHE to Improve the Diagnostic Performance of LI-RADS for Malignant Hepatic Tumors.一种强调薄环状不典型增生结节样强化的改良靶样特征,以提高肝脏影像报告和数据系统(LI-RADS)对恶性肝肿瘤的诊断性能。
J Hepatocell Carcinoma. 2024 Apr 26;11:775-786. doi: 10.2147/JHC.S448257. eCollection 2024.

本文引用的文献

1
First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges.不可切除肝细胞癌的一线免疫检查点抑制剂联合治疗:当前的管理和未来的挑战。
Expert Rev Gastroenterol Hepatol. 2021 Nov;15(11):1245-1251. doi: 10.1080/17474124.2021.1973431. Epub 2021 Aug 31.
2
PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials?PD-L1、TMB 及其他可能影响肝癌免疫治疗应答的预测因子:它们如何帮助药物临床试验?
Expert Opin Investig Drugs. 2022 Apr;31(4):415-423. doi: 10.1080/13543784.2021.1972969. Epub 2021 Aug 30.
3
Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma?
乐伐替尼联合帕博利珠单抗:肝癌治疗的下一个前沿?
Expert Opin Investig Drugs. 2022 Apr;31(4):371-378. doi: 10.1080/13543784.2021.1948532. Epub 2021 Jun 30.
4
CEUS LI-RADS Categories to Distinguish Hepatocellular Carcinoma and Non-Hepatocellular Carcinoma Malignancies.用于区分肝细胞癌和非肝细胞癌恶性肿瘤的CEUS LI-RADS分类
Radiology. 2020 Aug;296(2):E121-E122. doi: 10.1148/radiol.2020200623. Epub 2020 May 12.
5
Diagnostic Accuracy of CEUS LI-RADS for the Characterization of Liver Nodules 20 mm or Smaller in Patients at Risk for Hepatocellular Carcinoma.CEUS LI-RADS 在肝癌风险患者中对 20mm 或更小的肝脏结节的特征诊断准确性。
Radiology. 2020 Feb;294(2):329-339. doi: 10.1148/radiol.2019191086. Epub 2019 Dec 3.
6
Impact of Implementing a "FIB-4 First" Strategy on a Pathway for Patients With NAFLD Referred From Primary Care.实施“先FIB-4”策略对基层医疗转诊的非酒精性脂肪性肝病患者诊疗路径的影响
Hepatol Commun. 2019 Jul 29;3(10):1322-1333. doi: 10.1002/hep4.1411. eCollection 2019 Oct.
7
Hepatocellular carcinoma: an update on investigational drugs in phase I and II clinical trials.肝细胞癌:I 期和 II 期临床试验中研究药物的最新进展。
Expert Opin Investig Drugs. 2019 Nov;28(11):941-949. doi: 10.1080/13543784.2019.1677606. Epub 2019 Oct 12.
8
Distinguishing intrahepatic cholangiocarcinoma from hepatocellular carcinoma in patients with and without risks: the evaluation of the LR-M criteria of contrast-enhanced ultrasound liver imaging reporting and data system version 2017.在有和无风险因素的患者中鉴别肝内胆管细胞癌和肝细胞癌:对比增强超声肝脏成像报告和数据系统 2017 版 LR-M 标准的评估。
Eur Radiol. 2020 Jan;30(1):461-470. doi: 10.1007/s00330-019-06317-2. Epub 2019 Jul 11.
9
Global liver disease burdens and research trends: Analysis from a Chinese perspective.全球肝脏疾病负担与研究趋势:中国视角分析。
J Hepatol. 2019 Jul;71(1):212-221. doi: 10.1016/j.jhep.2019.03.004. Epub 2019 Mar 12.
10
Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: a proof of concept.节拍卡培他滨与最佳支持治疗在 Child-Pugh B 级肝癌中的比较:概念验证。
Sci Rep. 2018 Jul 3;8(1):9997. doi: 10.1038/s41598-018-28337-6.